Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published May 8, 2020 | Supplemental Material
Journal Article Open

Switchable Membrane Remodeling and Antifungal Defense by Metamorphic Chemokine XCL1

Abstract

Antimicrobial peptides (AMPs) are a class of molecules which generally kill pathogens via preferential cell membrane disruption. Chemokines are a family of signaling proteins that direct immune cell migration and share a conserved α–β tertiary structure. Recently, it was found that a subset of chemokines can also function as AMPs, including CCL20, CXCL4, and XCL1. It is therefore surprising that machine learning based analysis predicts that CCL20 and CXCL4's α-helices are membrane disruptive, while XCL1's helix is not. XCL1, however, is the only chemokine known to be a metamorphic protein which can interconvert reversibly between two distinct native structures (a β-sheet dimer and the α–β chemokine structure). Here, we investigate XCL1's antimicrobial mechanism of action with a focus on the role of metamorphic folding. We demonstrate that XCL1 is a molecular "Swiss army knife" that can refold into different structures for distinct context-dependent functions: whereas the α–β chemokine structure controls cell migration by binding to G-Protein Coupled Receptors (GPCRs), we find using small angle X-ray scattering (SAXS) that only the β-sheet and unfolded XCL1 structures can induce negative Gaussian curvature (NGC) in membranes, the type of curvature topologically required for membrane permeation. Moreover, the membrane remodeling activity of XCL1's β-sheet structure is strongly dependent on membrane composition: XCL1 selectively remodels bacterial model membranes but not mammalian model membranes. Interestingly, XCL1 also permeates fungal model membranes and exhibits anti-Candida activity in vitro, in contrast to the usual mode of antifungal defense which requires Th17 mediated cell-based responses. These observations suggest that metamorphic XCL1 is capable of a versatile multimodal form of antimicrobial defense.

Additional Information

© 2020 American Chemical Society. Received: January 9, 2020; Published: April 3, 2020. This work was supported in part by National Institutes of Health Grants R01 AI058072 and R01 AI120655 and a Translational Grant from the National Psoriasis Foundation (to B.F.V.), K08 DE026189 (to A.R.H.), and F30 CA236182 (to A.F.D). A.R.H. was also supported by the Children's Hospital of Wisconsin Research Institute. A.F.D. is a member of the NIH supported (T32 GM080202) Medical Scientist Training Program at the Medical College of Wisconsin (MCW). J.d.A. is supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE-1650604. M.W.L. and G.C.L.W. are supported by NIH R01AI143730, NIH R01AI052453, NSF DMR1808459, and the National Psoriasis Foundation. E.Y.L. acknowledges support from the Systems and Integrative Biology Training Program (T32GM008185), the Medical Scientist Training Program (T32GM008042), and the Dermatology Scientist Training Program (T32AR071307) at UCLA, and an Early Career Research Grant from the National Psoriasis Foundation. Author Contributions: A.F.D. and M.W.L. are co-first authors, A.R.H., G.C.L.W., and B.F.V. conceived and planned experiments. A.F.D, M.W.L, J.d.A, B.F.V., and G.C.L.W. wrote the manuscript. A.F.D., M.W.L., and J.d.A prepared manuscript figures. A.F.D. produced and purified proteins and analyzed data. M.W.L., J.d.A., A.F.D., and E.Y.L. performed SAXS experiments, and M.W.L., J.d.A., and E.Y.L. analyzed data. J.d.A. screened chemokine sequences using the machine-learning classifier and analyzed results. J.H. performed in vitro Candida assays and both J.H. and A.R.H. analyzed results and assisted in manuscript revision. All authors have given approval to the final version of the manuscript. A.F.D. and M.W.L. contributed equally to this work. The authors declare the following competing financial interest(s): B.F.V. has ownership interests in Protein Foundry, LLC.

Attached Files

Supplemental Material - id0c00011_si_001.pdf

Files

id0c00011_si_001.pdf
Files (379.0 kB)
Name Size Download all
md5:c70a170db75a1f21ff240b5624bfaf77
379.0 kB Preview Download

Additional details

Created:
August 19, 2023
Modified:
October 20, 2023